Sabril Approval History

• FDA approved: Yes (First approved August 21st, 2009)
• Brand name: Sabril
• Generic name: vigabatrin
• Company: Lundbeck Inc.
• Treatment for: Epilepsy, Seizures

Sabril (vigabatrin) is an oral irreversible GABA-transaminase inhibitor for the treatment of Infantile Spasms and refractory complex partial seizures.

FDA Approval History for Sabril

Date	Article
Aug 21, 2009	Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies
Jan  9, 2009	FDA Advisory Committee Unanimously Recommends Sabril (vigabatrin) for the Treatment of Two Catastrophic Epilepsies
Feb 27, 2008	FDA Accepts for Review Ovation's Two NDA Submissions for Sabril

See also...

Sabril (vigabatrin) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.